Friedreich’s ataxia is a rare condition that has been documented as an inherited neurodegenerative disease. It is transmitted through an autosomal recessive model that causes gradual degeneration of the cerebral and spinal ganglia in patients. This disease is classified as a rare disease because its incidence is 2-3 cases per 100,000 population, and treatment is currently only available symptomatically. In collaboration with researchers from Palacky University (Czech Republic), out of a number of new synthesized and identified compounds one has shown promising bioactivity. It was decided to expand the library of these compounds seeking to increase biological activity.
The aim of this project is to develop a library of 5-(butylthio)-1,3,4-oxadiazol-2-yl substituted 1H-indole regioisomers and to investigate synthesis path for preparation of 1H-indole with 5-(alkylamino)-1,3,4 -oxadiazol-2-yl substituent. All compounds obtained during this project after detailed structure and purity studies will be sent to the Czech Republic for biological testing. Their ability to protect FA-fibroblasts from oxidative stress is expected to be investigated.
Project funding:
Project is funded by EU Structural Funds according to the 2014–2020 Operational Programme for the European Union Funds’ Investments priority “Development of scientific competence of researchers, other researchers, students through practical scientific activities” under Measure No. 09.3.3-LMT-K-712.
Project results:
The expected result of the project is the prepared 3-, 4-, 5- or 6-(5-(butylthio)-1,3,4-oxadiazol-2-yl )-1H-indole derivatives by and investigated option to use 1H-indol-3-ylcarbhydrazide to obtain 2-(1H-indol-3-yl)-5-(alkylamino)-1,3,4-oxadiazole derivatives.
Period of project implementation: 2021-09-01 - 2022-03-31
Project coordinator: Kaunas University of Technology
